PD-L1 expression on tumor cells was associated with poor OS in patients with DLBCL. (A) OS of the entire study cohort. (B) OS of patients who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like chemotherapy. (C) OS of patients according to mPD-L1 positivity.